Introduction {#s1}
============

The most widely used approach to remove pituitary adenomas since the 1960s has been the transsphenoidal route, executed using the operating microscope. This approach is generally regarded as being associated with good outcomes.[@R1] However, starting approximately 15 years ago and more so in the past 5 years, there has been a trend towards using endoscopic transsphenoidal techniques for the removal of pituitary adenomas.[@R2; @R3; @R4; @R5] Endoscopic techniques have been recommended reportedly because of their lesser invasiveness, fewer complications and overall better results compared to microscopic microsurgical techniques.[@R5] In the absence of significant randomised clinical trials on the subject, a systematic review of published results of microsurgical and endoscopic techniques in the treatment of pituitary adenomas may be appropriate in comparing the two techniques.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

The MEDLINE (1990 to present) and the EMBASE (1990 to present) databases were the information source used. The following keywords were searched individually or in association: pituitary, adenoma, sella, transsphenoidal, endoscopy, microscopic, Cushing\'s disease, prolactinoma, acromegaly, endonasal, minimally invasive surgery, complication, skull base and surgery. The included limits were: English for the language category and humans for the study category. The date of the last search was August 2011.

Study selection criteria {#s2b}
------------------------

Series with 10 or more patients with pituitary adenoma, operated on using either microscopic or endoscopic techniques were included. Manuscripts in which the approach was guided by the endoscope and tumour removal was carried out using the microscope were included in the microscope group. As the intent of this report was to analyse the results of papers in which transsphenoidal surgery (either endoscopic or microscopic) was deemed to be the best modality to treat pituitary adenoma, we excluded reports in which a decision had been made preoperatively to use a combined transsphenoidal and intracranial approach.[@R6] Series including mixed pathology and in which it was not possible to extrapolate the adenoma results were also excluded.[@R7; @R8; @R9; @R10; @R11]

Mined data {#s2c}
----------

Mined data include year of publication, study design, number and sex of subjects, size of the adenoma (micro vs macro), death, cerebrospinal fluid leak, meningitis, vascular complications, visual complications, diabetes insipidus transient and permanent, hypopituitarism, cranial nerve injury and complete versus partial resection. Vascular complications included carotid or other vessels injury, intracerebral haematoma, or any symptomatic intratumoral or intrasellar haemorrhage. Venous bleeding from the cavernous sinus was tabulated as a vascular complication when it prevented the completion of the surgical procedure. Epistaxis was not included among the vascular complications. Cerebrospinal fluid leak included all postoperative leaks and all patients who developed an intra-operative leak requiring lumbar drainage. Decreased postoperative anterior pituitary function did not include Cushing\'s patients receiving postoperative cortisol or patients in whom a hypophysectomy was carried out.

Statistical analysis {#s2d}
--------------------

There were 38 studies that fulfilled the inclusion criteria.[@R1] [@R3] [@R12; @R13; @R14; @R15; @R16; @R17; @R18; @R19; @R20; @R21; @R22; @R23; @R24; @R25; @R26; @R27; @R28; @R29; @R30; @R31; @R32; @R33; @R34; @R35; @R36; @R37; @R38; @R39; @R40; @R41; @R42; @R43; @R44; @R45; @R46; @R47] All of them except one that was prospective and randomised[@R27] were retrospective studies. Only eight out of these 38 studies reported data on complications from both the endoscopic and microscopic surgery groups.[@R15] [@R17] [@R18] [@R21] [@R27] [@R32] [@R36] [@R45] Only one of these eight studies was prospective and randomised, with only 10 patients in each arm,[@R27] the others being retrospective studies. In six out of these seven studies the endoscopic and microscopic patients were accrued along longitudinally different time frames.[@R17] [@R18] [@R21] [@R32] [@R36] [@R45] Furthermore, in two of these seven studies tumour resection was either not evaluated at all,[@R15] or was judged by the surgeon at the time of the operation.[@R45] In addition, not all of these studies reported data on other relevant metrics (ie, tumour size, vascular and or visual complications). Due to the overall limitations of these studies we felt that we could have got more useful information by analysing all the data reported in the literature that fulfilled our inclusion criteria. Given the nature of the studies available in the literature it was not possible to compare the results (eg, complication rates) of endoscopic surgery to microscopic surgery using the traditional meta-analysis method with relative risk or OR. Instead, weighted summary rates and 95% CI of death and major complications/events (cerebrospinal fluid leak, meningitis, vascular complications, visual loss, diabetes insipidus temporary or permanent, hypopituitarism, complete resection, and nerve injury) were provided using the appropriate meta-analysis models (ie, random effects or fixed effects) for endoscopic and microscopic surgery, respectively. Then we compared the outcomes between endoscopic and microscopic surgery using the estimated proportions and SE (ie, 95% CI). Freeman--Tukey double arcsine transformation is used for proportions.[@R48] Tests for heterogeneity were performed for each meta-analysis. Based on results of the heterogeneity, test, random-effects (heterogeneity present) or fixed-effects (heterogemeity absent) models were chosen to estimate the results.[@R49] Using this methodology, each study was weighted more fairly than giving more weight to those studies with larger sample sizes, especially when the interstudy variation was larger than the intrastudy variation. Tabaee *et al*[@R5] used this methodological approach in 2009 when reviewing endoscopic pituitary surgery. The meta-analysis was performed using 'meta' package from the R statistical software.[@R50]

Results {#s3}
=======

Sixteen manuscripts dealt with transsphenoidal endoscopic removal of pituitary tumours,[@R3] [@R13] [@R14] [@R16] [@R20] [@R22] [@R23] [@R25] [@R29] [@R34] [@R35] [@R38] [@R40] [@R43] [@R44] [@R47] and 14 manuscripts reported on transsphenoidal removal of pituitary tumours using the operating microscope.[@R1] [@R12] [@R19] [@R24] [@R26] [@R28] [@R30] [@R31] [@R33] [@R37] [@R39] [@R41] [@R42] [@R46] Eight manuscripts included both techniques.[@R15] [@R17] [@R18] [@R21] [@R27] [@R32] [@R36] [@R45] Study type and demographics of all the studies are presented in [table 1](#JNNP2012303194TB1){ref-type="table"}.

###### 

Study types and demographics

  Authors                      Year   Duration of study   Operation type   No of patients   Mean age, years (range)   Women (%)   Macroadenomas (%)
  ---------------------------- ------ ------------------- ---------------- ---------------- ------------------------- ----------- -------------------
  Jho and Carrau[@R3]          1997   1993--6             Endoscopic       44               38 (14--88)               19 (43)     31 (70)
  Cappabianca *et al*[@R14]    2002   1997--2001          Endoscopic       146              46.1 (16--74)             76 (52)     125 (86)
  White *et al*[@R45]          2004   2000--2             Endoscopic       50               41.1 (NA)                 26 (52)     NA
  Senior *et al*[@R40]         2008   NA                  Endoscopic       148              46 (NA)                   81 (55)     114 (81)†
  Netea-Meier *et al*[@R35]    2006   1998--2004          Endoscopic       35               41 (14--68)               25 (71)     6 (17)
  Rudnik *et al*[@R38]         2005   2001--2             Endoscopic       63               48.3 (11--77)             34 (54)     52 (83)
  Kenan *et al*[@R29]          2006   1997--2005          Endoscopic       78               44.7 (11--67)             NA          67 (86)
  Jain *et al*[@R27]           2007   NA                  Endoscopic       10               40.1 (NA)                 6 (60)      9 (90)
  Uren *et al*[@R43]           2007   2001--5             Endoscopic       32               53 (25--69)               12 (38)     23 (72)
  Frank *et al*[@R22]          2006   1998--2004          Endoscopic       381              48 (7--89)                227 (60)    284 (75)
  Dehdashti *et al*[@R20]      2008   2004--7             Endoscopic       200              49.9 (20--78)             109 (55)    158 (79)
  Charalampaki *et al*[@R16]   2007   2004--5             Endoscopic       50               56 (28--84)               30 (60)     41 (82)
  Yano *et al*[@R44]           2009   2001--8             Endoscopic       194              53 (15--85)\*             120 (62)    NA
  Zhang *et al*[@R47]          2008   1998--2005          Endoscopic       78               45.1 (15--76)             42 (54)     67 (86)
  Campbell *et al*[@R13]       2010   2005--9             Endoscopic       26               45.7 (20--69)             12 (46)     22
  Gondim *et al*[@R23]         2010   1998--2009          Endoscopic       301              42 (12--79)               167 (55)    248
  Hofstetter *et al*[@R25]     2010   2004--10            Endoscopic       24               50.7 (22--75)             11 (46)     19
  Nakao *et al*[@R34]          2011   2000--8             Endoscopic       43               55 (31--75)               20 (46)     43
  Casler *et al*[@R15]         2005   1996--2003          Endoscopic       15               41.6                      9 (60)      NA
  Duz *et al*[@R21]            2008   1996--2007          Endoscopic       28               NA                        NA          NA
  Choe *et al*[@R17]           2008   2004--7             Endoscopic       12               47±12                     7 (58)      9
  O\'Malley *et al*[@R36]      2008   2003--8             Endoscopic       25               47.9 (18--73)             10 (40)     22
  D\'Haens *et al*[@R18]       2009   2001--7             Endoscopic       60               37 (10--70)               41 (68)     31
  Messerer *et al*[@R32]       2011   2006--9             Endoscopic       82               57 (20--82)               35 (43)     82
  Jain *et al*[@R27]           2007   NA                  Microscopic      10               31.6 (18--58)             5 (50)      8 (80)
  Mortini *et al*[@R33]        2005   1990--2002          Microscopic      1140             43 (8--82)                681 (60)    788 (69)
  Höybye *et al*[@R26]         2004   1990--9             Microscopic      34               40 (13--74)               26 (76)     2 (6)
  White *et al*[@R45]          2004   1996--9             Microscopic      50               43.5 (NA)                 17 (34)     NA
  Ciric *et al*[@R1]           1997   NA                  Microscopic      638              NA                        NA          NA
  De *et al*[@R19]             2003   1980--2001          Microscopic      90               61 (29--86)               46 (51)     61 (68)
  Rees *et al*[@R37]           2002   1980--2000          Microscopic      54               41.3 (14--73)             42 (78)     10 (19)
  Shimon *et al*[@R42]         2002   1990--2000          Microscopic      74               39 (8--72)                64 (86)     3 (4)
  Han *et al*[@R24]            2008   1996--2006          Microscopic      592              42.3 (NA)                 274 (46)    592 (100)‡
  Kaltsas *et al*[@R28]        2001   1993--8             Microscopic      67               46 (12--80)\*             31 (46)     50 (75)
  Kreutzer *et al*[@R31]       2001   1992--8             Microscopic      57               43.9 (16--71)             37 (65)     38 (67)
  Semple and Laws[@R39]        1999   1992--7             Microscopic      105              38.5 (6--78)              83 (79)     13 (12)
  Zhang *et al*[@R46]          1999   1982--97            Microscopic      208              47.5 (16--71)             110 (53)    208 (100)
  Koren *et al*[@R30]          1999   1993--5             Microscopic      37               NA                        NA          23 (62)
  Badie *et al*[@R12]          2000   1996--9             Microscopic      34               45.5 (NA)                 17 (50)     21 (62)
  Sheehan *et al*[@R41]        1999   1995--7             Microscopic      70               58.5 (25--85)             21 (30)     70 (100)
  Casler *et al*[@R15]         2005   1996--2003          Microscopic      15               50.6                      10 (67)     NA
  Choe *et al*[@R17]           2008   1997--2004          Microscopic      11               48±10                     9 (82)      8
  O\'Malley *et al*[@R36]      2008   2003--8             Microscopic      25               50.8 (23--78)             10 (40)     23
  Duz *et al*[@R21]            2008   1996--2007          Microscopic      65               NA                        NA          NA
  D\'Haens *et al*[@R18]       2009   2001--7             Microscopic      60               35 (10--68)               16 (27)     27
  Messerer *et al*[@R32]       2011   2005                Microscopic      82               56.5 (27--84)             35 (43)     82

\*Median age.

†Adenoma size was only available in 140 of 148 patients.

‡Including 438 macro and 154 giant.

Estimated proportions with 95% CI of macro tumour size and women were obtained using meta-analysis techniques.

We failed to detect any statistically significant difference in the two groups regarding the proportion of macro tumour size (endoscopic: 79.75% with 95% CI of 73.20% to 85.58%; microscopic: 66.90% with 95% CI of 47.54% to 83.67%) and women (endoscopic: 54.49% with 95% CI of 51.44% to 57.52%; microscopic: 54.51% with 95% CI of 47.58% to 61.35%).

We also used meta-analysis techniques to estimate the death and complications rates. Based on the test of heterogeneity results, random-effects pooled or fixed-effects pooled rates were estimated for death, cerebrospinal fluid leak, meningitis, vascular complications, visual complication, diabetes insipidus temporary, diabetes insipidus permanent, hypopituitarism, complete resection and nerve injury with endoscopic and microscopic surgery, respectively ([table 2](#JNNP2012303194TB2){ref-type="table"}). Fixed-effects pooled estimates of the death rate with endoscopic and microscopic surgery were computed because there was no evidence of heterogeneity (p=0.84 and 1). The pooled death rates were 0.49% (95% CI 0.23% to 0.84%) and 0.23% (95% CI 0.10% to 0.42%) for endoscopic and microscopic surgery, respectively. The fixed-effects pooled meningitis rate (p=0.86, test for heterogeneity) for endoscopic surgery and the random-effects pooled meningitis rate (p\<0.0001, test for heterogeneity) for microscopic surgery were 1.11% (95% CI 0.64% to 1.71%) and 2.08% (95% CI 0.83% to 3.86%). The fixed-effects pooled estimates of vascular complications were calculated for endoscopic and microscopic surgery (p=0.87 and 0.39, test for heterogeneity), which were 1.58% (95% CI 1.07% to 2.19%, [figure 1](#JNNP2012303194F1){ref-type="fig"}) and 0.50% (95% CI 0.28% to 0.78%, [figure 2](#JNNP2012303194F2){ref-type="fig"}). The fixed-effects or random-effects pooled estimates of visual complication rate (p=0.50 and 0.04, heterogeneity) and nerve injury rate (p=0.48 and 0.01, heterogeneity) were calculated for endoscopic and microscopic surgery, respectively, and are listed in [table 2](#JNNP2012303194TB2){ref-type="table"}.

###### 

Estimated proportion with 95% CI of complications/events for endoscopy and microscopy

  Complication/events            No of studies for endoscopy   Proportion (95% CI) for endoscopy   No of studies for microscopy   Proportion (95% CI) for microscopy
  ------------------------------ ----------------------------- ----------------------------------- ------------------------------ ------------------------------------
  Death                          19                            0.49% (0.23% to 0.84%)†             18                             0.23% (0.10% to 0.42%)†
  Cerebrospinal fluid leak       24                            7.00% (4.84% to 9.52%)              19                             6.34% (3.86% to 9.37%)
  Meningitis                     13                            1.11% (0.64% to 1.71%)†             14                             2.08% (0.83% to 3.86%)
  Vascular complications\*       17                            1.58% (1.07% to 2.19%)†             12                             0.50% (0.28% to 0.78%)†
  Visual loss                    13                            0.72% (0.37% to 1.19%)†             14                             0.60% (0.23% to 1.14%)
  Diabetes insipidus temporary   18                            9.10% (6.57% to 11.99%)             14                             10.23% (6.50% to 14.69%)
  Diabetes insipidus permanent   21                            2.31% (1.41% to 3.41%)              15                             4.25% (1.96% to 7.36%)
  Hypopituitarism                17                            8.51% (5.16% to 12.59%)             12                             11.64% (5.14% to 20.32%)
  Complete resection             22                            68.77% (64.37% to 73.00%)           18                             64.44% (57.62% to 70.98%)
  Nerve injury                   8                             0.28% (0.05% to 0.71%)†             7                              0.53% (0.08% to 1.34%)

\*Vascular complication rate is higher using the endoscope than using the microscope (p\<0.0001).

†A fixed-effects pooled estimate is used for the proportions. Otherwise, a random-effects pooled estimate is used.

![Proportion of vascular complications with endoscopy. Test for heterogeneity: Q=10.01 on 16 degrees of freedom (p=0.87).](jnnp-2012-303194f01){#JNNP2012303194F1}

![Proportion of vascular complications with microscopy. Test for heterogeneity: Q=11.67 on 11 degrees of freedom (p=0.39).](jnnp-2012-303194f02){#JNNP2012303194F2}

The random-effects pooled estimates with 95% CI of cerebrospinal fluid leak rate (both p\<0.0001, test for heterogeneity), temporary diabetes insipidus rate (both p\<0.0001,heterogeneity), permanent diabetes insipidus rate (p=0.02 and \<0.0001, heterogeneity) and hypopituitarism rate (both p\<0.0001, heterogeneity) for endoscopic and microscopic surgery were also calculated and listed in [table 2](#JNNP2012303194TB2){ref-type="table"}. We failed to demonstrate any statistically significant difference in the pooled rate of death, cerebrospinal fluid leak, meningitis, visual complication, diabetes insipidus temporary, diabetes insipidus permanent, hypopituitarism, complete resection and nerve injury between endoscopic and microscopic surgery using the estimated proportions and SE. On the other hand, the vascular complication rate in endoscopic surgery is higher than in microscopic surgery ([figures 1](#JNNP2012303194F1){ref-type="fig"} and [2](#JNNP2012303194F2){ref-type="fig"}, p\<0.0001) from those studies reporting the vascular complication information. Furthermore, the macro tumours or the extent of complete tumour resection, two variables that could have affected the vascular complication rate, were found not to be statistically significant in the endoscopic or microscopic series reporting vascular complications (p=0.24 and 0.10 for macro tumour size and complete resection, respectively).

Discussion {#s4}
==========

Transsphenoidal microscopic pituitary surgery {#s4a}
---------------------------------------------

Transsphenoidal microscopic pituitary surgery is a time confirmed effective way of treating pituitary adenomas, as shown by the low incidence of complications in any clinical/practice setting according to the Ciric-sponsored survey of the late 1990s,[@R1] although a statistically significant difference was noted in terms of better results in the hands of more experienced surgeons. Microscopic pituitary surgery relies on three-dimensional visualisation and thus on the ability to operate in three-dimensional space. Important conceptual nuances that need to be implemented in its execution to lead to optimal results are the recognition that the pituitary gland is a midline, extra-arachnoidal structure, and that the normal anterior pituitary gland is distended by the macroadenoma into a thin layer of tissue surrounding the pathology, whose preservation maximises postoperative pituitary function.[@R51] Therefore, microscopic pituitary surgery needs to be extra-arachnoidal, to respect the principle of midline and needs to try to identify and preserve normal pituitary tissue.

Endoscopic pituitary surgery {#s4b}
----------------------------

Endoscopic pituitary surgery has been advocated for the surgical treatment of pituitary adenomas since the late 1990s on the basis of its panoramic improved visualisation and thus the ability to visualise structures easily such as the optico-carotid recesses and to access suprasellar areas visually that are not in the direct line of vision during microscopic pituitary surgery.[@R5] [@R20] [@R22] This improved visualisation was felt to be theoretically associated with a greater extent of resection and improved safety, less invasiveness and potential better results---compared to microscopic pituitary surgery.[@R5] However, endoscopic pituitary surgery is bidimensional and thus depth perception is missing, although manoeuvres have been recommended to minimise this drawback.[@R21] The three surgical principles as described under microscopic surgery should also be applicable to endoscopic surgery.

Results of our study {#s4c}
--------------------

Our study did not demonstrate any short-term advantages of endoscopic pituitary adenoma surgery. The review of the literature suggests an increased incidence of vascular complications associated with it. Recognising the limitations of a systematic review in coming to firm conclusions, it is conceivable that the greater incidence of vascular complications associated with the endoscopic transsphenoidal surgical technique is the consequence of either a more robust sphenoid exposure of the carotid optic recess with a greater potential for carotid artery injury, or the lack of three-dimensional depth perception during suprasellar manoeuvres. Indeed, the majority of vascular complications associated with the endoscopic technique involved suprasellar vascular injuries including intracerebral haemorrhages, midbrain stroke, mesencephalic haemorrhage, posterior cerebral artery laceration and internal carotid artery injury.[@R14] [@R16] [@R22] [@R40]

Other possible advantages of endoscopic pituitary surgery {#s4d}
---------------------------------------------------------

Other theoretical advantages of endoscopic pituitary surgery such as its limited invasiveness or minimally invasive feature, leading to an overall better quality of life, have not been addressed by our study.[@R16] [@R29] [@R38] [@R40] [@R47] Indeed, the only study that looked at outcome and quality of life after endoscopic surgery for pituitary adenomas showed only 'a trend to improved scores in the endoscopic group compared with previous studies in patients treated by conventional approaches'.[@R52] A recent study has reported a 29.6% incidence of extracranial complications following endoscopic transsphenoidal sellar surgery, with the majority of them being prolonged nasal crusting (10.8%) and synechiae formation (8.8%).[@R53] Again, without making a definitive statement, it appears plausible that these nasal complications are the consequence of liberal and repetitive passage of instrumentation through the nasal cavity. That is even more likely to occur whenever nasal septal flaps are developed. Postoperative nasal debridement is usually required.[@R8]

Other systematic reviews {#s4e}
------------------------

There are three systematic reviews comparing endoscopic to microscopic pituitary adenoma removal.[@R54; @R55; @R56] One such review[@R55] is difficult to evaluate due to the fact that it includes, among other things, mixed patient/pathology cohorts in which endonasal microscopic surgery '...in some cases with endoscopic assistance' was compared to a sublabial microscopic technique.[@R57] The other two reviews, one analysing 11[@R54] and the other 10 studies,[@R56] with the same 10 studies being evaluated by both, reached somewhat different conclusions. Goudakos *et al*[@R54] indicated that the occurrence of diabetes insipidus, rhinological complications and length of hospital stay was significantly less in the endoscopic than in the microscopic group, while rates of complete tumour resection, cerebrospinal fluid leak, operative time and blood loss were not different in the two groups. The other review[@R56] shows that the purely endoscopic approach was linked to less blood loss, shorter hospital stay, shorter operative times and fewer nasal complications, but a higher incidence of cerebrospinal fluid leak than the microscopic approach, while other outcomes and complication rates were the same in the two groups.

Our review analysed a total of 5643 patients, of which were 2125 operated using the endoscope and 3518 using the microscope; data on vascular complications were available in 1887 patients operated with the endoscope and 3023 patients operated using the microscope. This is in contrast to 812 patients (373 endoscopic and 430 microscopic),[@R54] 549 patients (236 endoscopic and 313 microscopic)[@R55] and 687 patients (314 endoscopic and 373 microscopic)[@R56] collated by the three other systematic reviews.

Perspective {#s4f}
-----------

The need for careful evaluation of surgical innovations led to the convening of the Balliol colloquium and the Balliol collaboration at Balliol College in Oxford, UK, between 2007 and 2009. Participants included surgeons, methodologists, statisticians and the evidence-based medicine community. The results of such an effort were published in 2009.[@R58] Suffice it to say that notwithstanding transformative innovations such as tracheotomy for tracheal obstruction, leading to 'an advance that is clear and substantial and that cannot be explained by either chance or bias' the majority of surgical innovations are incremental and are 'prone to overoptimistic assessments by their developers and, therefore, need controlled randomised studies, when possible'.[@R58] The colloquium proposed a progressive algorithm, 'the IDEAL recommendations', to evaluate surgical innovations.[@R58] Stage 1, the idea phase, should be prompted by the need for a new solution to a clinical problem. It is essentially the proof of a concept and is implemented in only a few patients with careful outcome---especially negative outcome---reporting.

Stage 2a, the development phase, involves the planned use of the procedure in a small group of selected patients to accrue outcome on the safety of the procedure and its technical and procedural success or lack thereof. Protocols should be registered beyond the surgeons' institution to secure equipoise and should undergo some form of ethical approval and informed research consent. It is our belief that endoscopic transsphenoidal surgery has fulfilled splendidly the requirements under these two progressive algorithm stages.

Stage 2b, the exploration phase, involves the evaluation of the outcome of a rather well-defined procedure in a larger group of patients. Rigorous prospective trials looking at short-term outcomes (technical clinical and patient centered) need to be employed in this stage. Clearly, stringent quality controls need to be in place.

Stage 3, the assessment phase, involves well-defined indications, a stable procedure executed by many surgeons and the comparison of this procedure with the gold standard procedure. This is usually done using randomised clinical trials or alternative well-structured trials, such as parallel group non-randomised studies, controlled interrupted-time series studies, tracker trials or similar designs. Again, institutional review board approval and informed research consent are mandatory.

Stage 4, the long-term study phase, is a surveillance study wherein the now established procedure is evaluated for rare and long-term outcomes. No ethical approval is necessary.

Endoscopic pituitary surgery and the IDEAL framework {#s4g}
----------------------------------------------------

It appears that 12 years after the publication of one of the first peer-reviewed papers on the use of endoscopic pituitary surgery[@R26] the advantages of the procedure are still not fully consolidated in accordance with the above algorithm for the evaluation of new surgical techniques. Clearly, the introduction of new surgical technology/procedures, such as endoscopic transsphenoidal surgery, is both a laudatory step towards innovation as well as a complex process requiring rigorous scrutiny with evidence-based methods such as discussed above or a similar acceptable variant thereof.[@R58; @R59; @R60]

Conclusions {#s5}
===========

Meta-analysis of available literature on endoscopic transsphenoidal removal of pituitary adenomas seems to suggest that the endoscopic technique is associated with a higher incidence of vascular complications compared to microscopic transsphenoidal removal of pituitary adenomas. Moreover, in the short term, the same analysis of the literature reveals that there is no clear, unequivocal advantage to endoscopic transsphenoidal removal compared to microscopic transsphenoidal removal of pituitary adenomas.
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